Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Immunity. 2012 Apr 20;36(4):542-50. doi: 10.1016/j.immuni.2012.03.014.
The discovery of the Janus kinase (JAK)-signal transducer and activator of transcripton (STAT) signaling pathway, a landmark in cell biology, provided a simple mechanism for gene regulation that dramatically advanced our understanding of the action of hormones, interferons, colony-stimulating factors, and interleukins. As we learn more about the complexities of immune responses, new insights into the functions of this pathway continue to be revealed, aided by technology that permits genome-wide views. As we celebrate the 20(th) anniversary of the discovery of this paradigm in cell signaling, it is particularly edifying to see how this knowledge has rapidly been translated to human immune disease. Not only have genome-wide association studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.
Janus 激酶（JAK）-信号转导子和转录激活子（STAT）信号通路的发现，是细胞生物学的一个里程碑，为基因调控提供了一个简单的机制，极大地促进了我们对激素、干扰素、集落刺激因子和白细胞介素作用的理解。随着我们对免疫反应复杂性的了解不断深入，借助允许全基因组观察的技术，该通路的功能不断有新的发现。在我们庆祝这一细胞信号转导范例发现 20 周年之际，特别值得欣慰的是，我们看到这一知识是如何迅速转化为人类免疫疾病的。全基因组关联研究不仅表明该通路与人类自身免疫性疾病高度相关，而且靶向 JAK 现在已经成为免疫介导疾病的现实。
